Clover Biopharmaceuticals Ltd. (HK:2197) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Clover Biopharmaceuticals Ltd. reported a significant downturn, posting a loss of RMB 95.1 million for the first half of 2024, compared to a profit of RMB 650.6 million in the same period last year. This decline was attributed to non-recurring income from funding and a lack of inventory impairment provisions that bolstered the previous year’s results. Cost cuts in administration, sales, and R&D failed to offset the losses, with cash and bank balances also decreasing by RMB 265.7 million from the end of 2023.
For further insights into HK:2197 stock, check out TipRanks’ Stock Analysis page.